Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Po Yee Yip"'
Autor:
Udit Nindra, Adel Shahnam, Samuel Stevens, Abhijit Pal, Adnan Nagrial, Jenny Lee, Po Yee Yip, Tamiem Adam, Michael Boyer, Steven Kao, Victoria Bray
Publikováno v:
Thoracic Cancer, Vol 13, Iss 21, Pp 3058-3062 (2022)
Abstract Sustained elevation in neutrophil‐to‐lymphocyte ratio (NLR) after initial chemoradiotherapy (CRT) has been shown to correlate with worse prognosis in a number of solid organ malignancies. Here, we conducted a retrospective observational
Externí odkaz:
https://doaj.org/article/7a4cd723958e4e11906e35ac25e41b11
Autor:
Tamkin Ahmadzada, BE, Wendy A. Cooper, BScMed, M.B.B.S., PhD, FRCPA, Mikaela Holmes, BBiomedSc, Annabelle Mahar, M.B.B.S., FRCPA, Helen Westman, MPH, Anthony J. Gill, MD, FRCPA, Ina Nordman, M.B.B.S., FRACP, M(Med)Sc, Po Yee Yip, MbChB., FRACP, PhD, Abhijit Pal, BSc (Hons), M.B.B.S., FRACP, Rob Zielinski, FRACP, M.B.B.S., Hons, Nick Pavlakis, BSc, M.B.B.S., MMed (Clin Epi), PhD, FRACP, Adnan Nagrial, M.B.B.S., PhD, Dariush Daneshvar, MD, FRCPA, Daniel Brungs, M.B.B.S., MMed (Clin Epi), FRCPA, Deme Karikios, BSc, M.B.B.S., FRACP, PhD, Vesna Aleksova, BMedSc, Juliet Burn, M.B.B.S., FRCPA, MIAC, Rebecca Asher, MSc, Georges E. Grau, MD, PhD, Elham Hosseini-Beheshti, MSc, PhD, Glen Reid, PhD, Stephen Clarke, MD, PhD, FRACP, Steven Kao, BHB, MbChB., PhD, FRACP
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 4, Pp 100075- (2020)
Introduction: We investigated the efficacy and toxicity of pembrolizumab in patients with mesothelioma from a real-world Australian population. We aimed to determine clinical factors and predictive biomarkers that could help select patients who are l
Externí odkaz:
https://doaj.org/article/8decaaa69f954183bf0aaa4a972c4d8b
Publikováno v:
Internal Medicine Journal.
Extrapulmonary small cell cancer (EPSCC) is a rare malignancy with an incidence of approximately 0.1%-0.4% of all cancers. Treatment of this disease is often based on small cell lung cancer.We aimed to investigate real-world clinical outcomes of pati
Autor:
Benjamin Solomon, Tristan Shaffer, Po Yee Yip, S. Liang, Nick Pavlakis, Mark Li, Tristan A. Barnes, Malinda Itchins, Adnan Nagrial, G. Peters, Stephen Clarke, S. Kao, Christopher L. Brown, Venessa T. Chin, Craig R. Lewis, Bob T. Li, Gavin Marx, Victoria J Bray
Publikováno v:
Journal of Thoracic Oncology. 16:S1030-S1032
Autor:
Malinda Itchins, Hannah Ainsworth, Marliese Alexander, Samantha Dean, Devi Dharmaraj, Nick Pavlakis, Stephen J. Clarke, Chris Brown, Javier Torres, Ayesha Saqib, Rahul Ladwa, Kenneth O'Byrne, Melissa Moore, Po Yee Yip, Ben Solomon, Tom John, Steven Kao, Paul Mitchell, Sagun Parakh
Publikováno v:
Clinical lung cancer. 23(8)
There are limited real world data on the IMpower150 regimen in oncogene driven tumors and central nervous system metastases; this study aims to address this gap.Retrospective analysis of patients with advanced non-small cell lung cancer treated with
Autor:
Udit Nindra, Samuel Xavier Stevens, Adel Shahnam, Abhijit Pal, Tamiem Adam, Po Yee Yip, Jenny HJ Lee, Michael J. Boyer, Adnan Nagrial, Steven Chuan-Hao Kao, Victoria Jane Bray
Publikováno v:
Journal of Clinical Oncology. 40:e18810-e18810
e18810 Background: The PACIFIC trial established concurrent chemoradiation followed by one year of consolidation durvalumab as the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). However, the data to support the use of
Autor:
Udit Nindra, Adel Shahnam, Samuel Xavier Stevens, Abhijit Pal, Po Yee Yip, Tamiem Adam, Jenny HJ Lee, Michael J. Boyer, Adnan Nagrial, Steven Chuan-Hao Kao, Victoria Jane Bray
Publikováno v:
Journal of Clinical Oncology. 40:e18773-e18773
e18773 Background: The neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) has been of prognostic interest in lung cancer. Sustained NLR and PLR after initial chemoradiotherapy (CRT) has been shown to correlate with worse prog
Autor:
Samuel Xavier Stevens, Udit Nindra, Adel Shahnam, Victoria Jane Bray, Po Yee Yip, Tamiem Adam, Jenny HJ Lee, Michael J. Boyer, Adnan Nagrial, Steven Chuan-Hao Kao
Publikováno v:
Journal of Clinical Oncology. 40:e18809-e18809
e18809 Background: Consolidation treatment with durvalumab following CRT is now standard of care for pts with unresectable stage III NSCLC. In PACIFIC, durvalumab was administered within 42 days of completing CRT. There has also been recent interest
Autor:
Nick Pavlakis, Paul Mitchell, R. Ladwa, Benjamin Solomon, S. Kao, Stephen Clarke, D. Dharmaraj, Po Yee Yip, Marliese Alexander, Melissa M. Moore, Sagun Parakh, S. Dean, R. Tay, Malinda Itchins, Thomas John, A. Saqib, Javier Torres, Hannah Ainsworth, Rachel O'Connell
Publikováno v:
Journal of Thoracic Oncology. 16:S1015-S1016
Autor:
Tara L. Roberts, Po Yee Yip, Joseph Descallar, Therese M. Becker, Victoria J Bray, Pei N Ding, Wei Chua
Publikováno v:
Internal Medicine Journal. 47:1405-1411
Background Epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) is a subgroup of oncogene addicted lung cancer that predicts response to tyrosine kinase inhibitors (TKI). However, there is variability in response and sur